Hsbc Holdings PLC lifted its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) by 7.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 34,343 shares of the company’s stock after buying an additional 2,329 shares during the period. Hsbc Holdings PLC’s holdings in MiMedx Group were worth $233,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after buying an additional 413,443 shares in the last quarter. Harbor Capital Advisors Inc. bought a new position in MiMedx Group in the second quarter valued at approximately $1,781,000. Cannell Capital LLC raised its position in MiMedx Group by 9.1% during the fourth quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock valued at $21,758,000 after purchasing an additional 207,207 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in MiMedx Group during the second quarter worth $988,000. Finally, Caxton Associates LP acquired a new stake in shares of MiMedx Group in the 1st quarter valued at $1,018,000. Institutional investors own 79.15% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have recently commented on MDXG shares. Craig Hallum lowered their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st. Finally, StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.00.
MiMedx Group Price Performance
Shares of MDXG opened at $5.76 on Friday. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The stock has a market cap of $850.20 million, a PE ratio of 13.09 and a beta of 1.97. MiMedx Group, Inc. has a 12-month low of $5.57 and a 12-month high of $9.27. The business has a 50-day simple moving average of $6.40 and a two-hundred day simple moving average of $6.89.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The company had revenue of $87.21 million during the quarter, compared to the consensus estimate of $88.44 million. Analysts anticipate that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
- Five stocks we like better than MiMedx Group
- Market Cap Calculator: How to Calculate Market Cap
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is a Dividend King?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc. (NASDAQ:MDXG – Free Report).
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.